09:04 AM EDT, 08/25/2025 (MT Newswires) -- HCW Biologics ( HCWB ) said Monday that its scientists have developed a second-generation, pembrolizumab-based immunotherapeutics against solid tumors, especially for pancreatic and ovarian cancer, using its TRBC platform.

The company said its pembrolizumab-based immune checkpoint inhibitor activated immune cells and promoted their infiltration into solid tumors at the same time in investigational new drug-enabling studies, details of which will be presented on Sept. 12.

Shares of HCW Biologics ( HCWB ) rose 65% in recent Monday premarket activity.